Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Department of Oncology, Hematology and Infectious Diseases, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Cancer Sci. 2021 Jan;112(1):433-443. doi: 10.1111/cas.14742. Epub 2020 Dec 7.
This study aimed to clarify the attitude of oncologists toward influenza vaccination and the current situation and issues regarding influenza vaccination for patients on chemotherapy in Japan. A web-based survey of medical oncologists certified by the Japanese Society of Medical Oncology was conducted between November 1 and December 31, 2019. Of the 1369 medical oncologists who were invited to participate, 415 (30.3%) responded to our survey. The questionnaire comprised 4 sections: "oncologist characteristics," "oncologist attitude toward influenza vaccines and the current status of influenza vaccination for cancer patients undergoing chemotherapy," "incidence of influenza infection and associated treatment complications," and "treatment policy for influenza infection." In total, 153 (36.9%) physicians replied that they did not actively encourage influenza vaccination for patients undergoing chemotherapy. The primary reasons given were lack of evidence (48/153, 31.4%) and uncertainty of appropriate timing (46/153, 30.1%). There was diverse variation in the timing of vaccination and in the levels of encouragement based on the cancer location and medication type. Two hundred eighty-three (68.2%) oncologists reported that their cancer patients had experienced influenza infection while undergoing chemotherapy, and 169 (40.7%) responded that their patients had experienced an administration delay or discontinuation of medication because of influenza infection. Our surveillance revealed some oncologists considered evidence regarding the administration of influenza vaccine to cancer patients undergoing chemotherapy (particularly the optimal timing and level of recommendation by cancer location and medication) to be lacking. It also exposed the adverse impact of influenza infection in cancer patients.
本研究旨在阐明日本肿瘤医师对流感疫苗接种的态度,以及目前癌症患者接受化疗时流感疫苗接种的现状和问题。我们对日本肿瘤内科学会认证的肿瘤内科医师进行了一项在线调查,调查于 2019 年 11 月 1 日至 12 月 31 日进行。在受邀参加的 1369 名肿瘤内科医师中,有 415 名(30.3%)对我们的调查做出了回应。问卷包括 4 个部分:“肿瘤内科医师特征”、“肿瘤内科医师对流感疫苗的态度和癌症患者接受化疗时流感疫苗接种的现状”、“流感感染的发生率及相关治疗并发症”和“流感感染的治疗政策”。共有 153 名(36.9%)医生表示他们不会积极鼓励接受化疗的癌症患者接种流感疫苗。主要原因是缺乏证据(48/153,31.4%)和时机不确定(46/153,30.1%)。基于癌症部位和药物类型,接种时机和鼓励程度存在差异。283 名(68.2%)肿瘤内科医师报告其癌症患者在接受化疗时曾发生流感感染,169 名(40.7%)医师报告其癌症患者因流感感染而导致药物治疗延迟或中断。我们的监测结果表明,一些肿瘤内科医师认为,癌症患者接受化疗时接种流感疫苗的相关证据(特别是基于癌症部位和药物类型的最佳接种时机和推荐级别)不足,同时也暴露出流感感染对癌症患者的不良影响。